Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK3486 Abuse Potential Study
NCT05614544Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cycloprofol in general anesthesia (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Evaluation of Abuse Potential at 2 days. Started Aug 2022; status: completed.
02
Drugs
cycloprofol
03
Conditions
general anesthesia
Beyond the preview
Go deeper on NCT05614544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614544.